Navigation Links
Perrigo Confirms FDA Approval For Testosterone Gel 1%
Date:2/5/2013

ALLEGAN, Mich., Feb. 5, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it has received U.S. Food and Drug Administration approval for its New Drug Application (NDA) for testosterone gel 1%. Perrigo's NDA included a bioequivalence study that compared its product to AbbVie's AndroGel® 1%.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

AndroGel® 1% (testosterone gel 1%) is indicated to treat adult males who have low or no testosterone. Annual sales were approximately $705 million annually, as measured by Symphony Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."          

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
2. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
3. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
4. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
5. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
6. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
7. Perrigo Company To Present At The Credit Suisse Healthcare Conference
8. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... , July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: ... southeast Michigan by Crain,s Detroit ... private and public companies by three-year revenue growth. This year,s ... To view the complete list, visit ... 50 is an incredible triumph," said Phil Hagerman , ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... 2017 , ... State Farm Neighborhood Assist® has named The Southern Maryland ... grant. If the initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl ... of St. Mary’s, Calvert and Charles Counties. The program could potentially impact nearly 17,500 ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... will feature the Aurum Group in an upcoming episode, slated to air fourth ... Innovations will feature the Aurum Group; a company committed to supporting dentistry using ...
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... database to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s ... faster technology with lower fees. Paragon will build a fully verifiable database to ...
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health and ... with pending recognition status from the Centers for Disease Control and Prevention (“CDC”) ... and live video conferencing. , The DPP resulted from clinical work conducted ...
(Date:8/19/2017)... ... 2017 , ... Praeclarus Press has launched a new ... the diversity of the breastfeeding mothers, using bright colors and contemporary themes. These ... are also available on tote bags, notepads, smartphone cases, clocks, and travel mugs. ...
Breaking Medicine News(10 mins):